Search Result

Results for "

TLR agonists

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Toll-like Receptor (TLR) (254) ADC Linker (1) ADC Payload (4) Akt (5) Aldehyde Oxidase (AO) (1) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (2) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (19) Aryl Hydrocarbon Receptor (1) Autophagy (11) Bacterial (5) Bcl-2 Family (3) Caspase (1) Cdc42-binding kinase (1) COX (1) Cytochrome P450 (1) DNA/RNA Synthesis (1) Drug Derivative (1) Drug Intermediate (1) Drug-Linker Conjugates for ADC (7) EGFR (3) Endogenous Metabolite (2) ERK (3) Galectin (1) HBV (7) HCV (7) HIV (6) HSP (4) HSV (11) IFNAR (10) IKK (3) Influenza Virus (4) Integrin (2) Interleukin Related (26) Isotope-Labeled Compounds (4) Keap1-Nrf2 (1) Liposome (1) MAPKAPK2 (MK2) (1) Mitosis (1) MMP (1) MyD88 (4) NF-κB (17) NO Synthase (9) NOD-like Receptor (NLR) (4) Nucleoside Antimetabolite/Analog (5) P-glycoprotein (1) p38 MAPK (6) PD-1/PD-L1 (3) PI3K (2) PKC (4) PKD (3) PPAR (3) PROTACs (1) Pyroptosis (2) Reactive Oxygen Species (ROS) (5) Reference Standards (15) RIG-I-like receptor (RLR) (4) SARS-CoV (12) Sirtuin (3) STAT (2) TNF Receptor (15)
By Research Areas:	Cancer (133) Cardiovascular Disease (11) Infection (55) Inflammation/Immunology (186) Metabolic Disease (4) Neurological Disease (12)
Click Chemistry:	Azide (2) Alkynes (1)
Oligonucleotides:	CpG ODNs (41) Cationic Lipids (1) Phospholipids (1) Adjuvant (4) Antisense Oligonucleotides (6)

271

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Targets Recommended: Toll-like Receptor (TLR)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13740

Resiquimod Maximum Cited Publications 110 Publications Verification R848; S28463	Toll-like Receptor (TLR) HCV	Inflammation/Immunology Cancer
Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.

HY-146245

ODN 1826 Maximum Cited Publications 10 Publications Verification CpG 1826	Toll-like Receptor (TLR) Apoptosis NO Synthase	Cardiovascular Disease Inflammation/Immunology Cancer
ODN 1826 is a class B CpG ODN (oligodeoxynucleotide) and *TLR9* agonist. ODN 1826 induces NO and iNOS production and enhances Apoptosis. ODN 1826 enhances immune surveillance. ODN 1826 increases aortic atherosclerotic plaque size. ODN 1826 has antitumor activity against lung cancer, glioma and melanoma .

HY-P1180A

Pam3CSK4 TFA Maximum Cited Publications 19 Publications Verification Pam3Cys-Ser-(Lys)4 TFA	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
Pam3CSK4 TFA is a toll-like receptor 1/2 (TLR1/2) agonist with an EC₅₀ of 0.47 ng/mL for human TLR1/2 .

HY-123942

Diprovocim 10+ Cited Publications	Toll-like Receptor (TLR) TNF Receptor p38 MAPK NF-κB	Inflammation/Immunology Cancer
Diprovocim is a potent *TLR1/TLR2* agonist. Diprovocim elicits full agonist activity in human THP-1 cells (EC₅₀=110 pM). Diprovocim stimulates the release of TNF-α from mouse macrophages (EC₅₀=1.3 nM). Diprovocim activates downstream MAPK and NF-κB signaling pathway. Diprovocim displays strong adjuvant activity in mice, particularly abetting cellular immune responses .

HY-103698A

TLR7/8 agonist 1 dihydrochloride 1 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7/8 agonist 1 dihydrochloride is a toll-like receptor *TLR7/TLR8* dual-agonistic imidazoquinoline .

HY-103697

Gardiquimod	Toll-like Receptor (TLR)	Cancer
Gardiquimod is an imidazoline TLR7/8 agonist. Gardiquimod inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 at concentrations below 10 μM.

HY-103698

TLR7/8 agonist 1 1 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7/8 agonist 1 is a toll-like receptor (TLR7)/TLR8 dual-agonistic imidazoquinoline.

HY-109104

Telratolimod 5+ Cited Publications MEDI9197; 3M-052	Toll-like Receptor (TLR)	Cancer
Telratolimod (MEDI9197) is a potent toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity .

HY-111358

TLR7 agonist 1	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 1 is a selective *TLR7* agonist with an LEC value of 90 nM. TLR7 agonist 1 activates downstream immune regulation and shows no activity against *TLR8. TLR7 agonist* 1 induces endogenous IFN-α production in mice .

HY-117602

TLR7 agonist 3 1 Publications Verification	Toll-like Receptor (TLR)	Neurological Disease Inflammation/Immunology Cancer
TLR7 agonist 3 (compound 2) is a *TLR7* agonist and can be used for the stuy of cancers .

HY-103039

TLR7 agonist 2 1 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 2 is a potent and selective Toll-like Receptor 7 (TLR7) agonist with a LEC of 0.4 μM.

HY-150750

ODN M362	Toll-like Receptor (TLR) Apoptosis	Inflammation/Immunology Cancer
ODN M362, a class C oligodeoxynucleotide, is a *TLR-9* agonist and can be used as a vaccine adjuvant. ODN M362 induces cancer cell apoptosis .

HY-P1180

Pam3CSK4 Pam3Cys-Ser-(Lys)4	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
Pam3CSK4 is a toll-like receptor 1/2 (TLR1/2) agonist with an EC₅₀ of 0.47 ng/mL for human TLR1/2 .

HY-138139A

AXC-715 hydrochloride T785 hydrochloride	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
AXC-715 (T785) hydrochloride is a *TLR7/TLR8* dual agonist. AXC-715 can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants .

HY-139017

TLR7/8 agonist 4	Toll-like Receptor (TLR)	Neurological Disease Inflammation/Immunology Cancer
TLR7/8 agonist 4 (compound 41) is a potent *TLR7/8* agonist. TLR7/8 agonist 4 has anti-cancer activity .

HY-145885

TLR7/8 agonist 6	Toll-like Receptor (TLR) TNF Receptor Interleukin Related IFNAR	Infection Inflammation/Immunology Cancer
TLR7/8 agonist 6 is a *TLR7/8* agonist with EC₅₀s of 0.18 μM and 5.34 μM in TLR7 or TLR8 HEK-SEAP reporter cells, respectively. TLR7/8 agonist 6 potently stimulates production of TNFα, IFNγ, and IL-1β. TLR7/8 agonist 6 can be used for research on cancer and infectious diseases .

HY-148338

TLR8 agonist 5	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR8 agonist 5 is a potent *TLR8* agonist with an EC₅₀ value of 20 nM for HEK-Blue hTLR8. TLR8 agonist 5 activates the immune response .

HY-130797

TLR7/8 agonist 3	Toll-like Receptor (TLR)	Cancer
TLR7/8 agonist 3 (Compound II) is a potent *TLR7* and *TLR8* agonist, extracted from patent WO2016057618 (compound of formula (II)) .

HY-139018A

TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride	Drug-Linker Conjugates for ADC	Cancer
TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride (compound 9) is a drug-linker conjugates for ADC with potent antitumor activity by using TLR7/8 agonist 4 (HY-139018; a TLR7/8 agonist), linked via the non-cleavable ADC linker hydroxy-PEG10-acid (HY-133307) .

HY-101929

CU-CPT17e 3 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
CU-CPT17e is a potent multi-Toll-like receptor (TLR) agonist that activates *TLR3, TLR8, and TLR9*.

HY-135905

CL264	Toll-like Receptor (TLR)	Inflammation/Immunology
CL264 is a *TLR7*-specific agonist for innate immune signals research .

HY-144619

TLR7/8 antagonist 2	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7/8 antagonist 2 (Compound 15) is a potent and orally active agonist of *TLR7/8* with IC₅₀s of 4.9 and 0.6 nM, respectively. Inappropriate activation of TLR7 and TLR8 is linked to several autoimmune diseases, such as lupus erythematosus. TLR7/8 antagonist 2 has the potential for the research of autoimmune diseases .

HY-103697A

Gardiquimod diTFA	Toll-like Receptor (TLR)	Cancer
Gardiquimod diTFA is an imidazoline TLR7/8 agonist. Gardiquimod diTFA inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 at concentrations below 10 μM.

HY-145961

TLR7 agonist 4	Toll-like Receptor (TLR) TNF Receptor	Cancer
TLR7 agonist 4 is a *TLR7* agonist with pro-inflammatory cytokine-stimulating activity. TLR7 agonist 4 modulates *TLR7* activity to stimulate the production of pro-inflammatory cytokines. TLR7 agonist 4 stimulates mouse bone marrow-derived macrophages to produce the pro-inflammatory cytokine TNFα. TLR7 agonist 4 can be conjugated with antibodies to form conjugates. TLR7 agonist 4 is applicable to cancer research .

HY-139018

TLR7/8 agonist 4 hydroxy-PEG10-acid	Drug-Linker Conjugates for ADC	Cancer
TLR7/8 agonist 4 hydroxy-PEG10-acid (compound 9) is a drug-linker conjugates for ADC with potent antitumor activity by using TLR7/8 agonist 4 (HY-139018; a TLR7/8 agonist), linked via the non-cleavable ADC linker hydroxy-PEG10-acid (HY-133307) .

HY-163398

TLR7-IN-1	Toll-like Receptor (TLR)	Cancer
TLR7-IN-1 (Compound 16-A) is a *TLR7* agonist with an EC₅₀ of 0.001 μM. TLR7-IN-1 is applicable to cancer-related research .

HY-13740S

Resiquimod-d5 1 Publications Verification R848-d₅; S28463-d₅	Isotope-Labeled Compounds Toll-like Receptor (TLR) HCV	Infection Inflammation/Immunology
Resiquimod-d₅ is deuterium labeled Resiquimod. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α .

HY-145886

TLR7/8 antagonist 1	Toll-like Receptor (TLR) Interleukin Related	Infection Inflammation/Immunology Cancer
TLR7/8 antagonist 1 (Compound 16c) is a competitive *TLR7/8* antagonist with IC₅₀ values of 3.91 μM and 2.19 μM, respectively. TLR7/8 antagonist 1 reduces agonist-induced production of proinflammatory cytokines, including TNFα, IFNγ and IL-1β .

HY-156691A

TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride	Drug-Linker Conjugates for ADC	Cancer
TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride is a drug-linker conjugates for ADC>. TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride is the hydrochloride form of TLR7/8 agonist 4 hydroxy-PEG6-acid. TLR7/8 agonist 4 hydroxy-PEG6-acid consists of TLR7/8 agonist 4 (HY-139017) and a non-cleavable linker Hydroxy-PEG6-acid (HY-133050), and can be used for synthesis of ADCs .

HY-153073

TLR7 agonist 8	Toll-like Receptor (TLR) Interleukin Related	Infection Inflammation/Immunology Cancer
TLR7 agonist 8 is a *TLR7* agonist with an EC₅₀ of 0.12 nM for TLR7 and an EC₅₀ of 0.76 nM for IL-6 induction. TLR7 agonist 8 can be used for research on diseases such as fibrosis, inflammatory diseases, cancer, or pathogen infections .

HY-153070

TLR7 agonist 5	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 5 (compound IIb-11) is an *TLR7* agonist with an EC₅₀ value of ~4 nM .

HY-158694A

TLR7 agonist 20 hydrochloride	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 20 hydrochloride is a selective Toll-like receptor 7 (TLR7) agonist with an EC₅₀ of 0.22 μM. TLR7 agonist 20 hydrochloride, as an immunostimulant and vaccine adjuvant, enhances the production of anti-spike protein antibodies, increases IgG2b and IgG2c levels, and thereby drives Th1-type immune responses in mice. TLR7 agonist 20 hydrochloride can be used in studies related to non-inflammatory potent vaccine adjuvants .

HY-176202

TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC	Drug-Linker Conjugates for ADC	Cancer
TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC (compound LIV1-IMC (12) linker-payload) is a linker-payload conjugate, used in the synthesis of antibody-drug conjugates (ADCs).TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC contains TLR7/8 agonist (HY-170770) (ADC payload) and a linker (HY-176478) .

HY-138139B

AXC-715 trihydrochloride T785 trihydrochloride	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
AXC-715 (T785) trihydrochloride is a *TLR7/TLR8* dual agonist. AXC-715 trihydrochloride can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants .

HY-147310

CU-CPD107	Toll-like Receptor (TLR)	Infection
CU-CPD107 is a potent, selective *toll-like receptor 8 (TLR* 8)** agonist. CU-CPD107 inhibits TLR8 signaling. CU-CPD107 converts to synergistic agonist activities in the presence of ssRNA and induces TLR8 signaling. CU-CPD107 inhibits proinflammatory factor expression and avoids immune responses in the presence of ssRNA .

HY-176837

*NOD2/TLR4 agonist-1*	Toll-like Receptor (TLR) NOD-like Receptor (NLR)	Inflammation/Immunology
NOD2/TLR4 agonist-1 (Compound 2) is a *NOD2/TLR4* dual agonist. NOD2/TLR4 agonist-1 lacks immunostimulatory activity and serves as an important negative control in research .

HY-179336

TLR7/8 agonist 14	Toll-like Receptor (TLR) Interleukin Related IFNAR TNF Receptor	Cancer
TLR7/8 agonist 14 is a *TLR7* and *TLR8* agonist with EC₅₀ values of 0.53 μM and 4.3 μM, respectively. TLR7/8 agonist 14 increases the secretion of the proinflammatory cytokines TNF-α, IL-1β, IL-8 and IFN-γ. TLR7/8 agonist 14 increases cytokine secretion and expression of CD86. LR7/8 agonist 14 can be used for research colorectal carcinoma .

HY-145960

*MC-Val-Cit-PAB-Amide-TLR7 agonist* 4**	EGFR Toll-like Receptor (TLR)	Inflammation/Immunology
MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a *HER2-TLR7* and *HER2-TLR8* immune agonist conjugate .

HY-173070

TLR7 agonist 29	Toll-like Receptor (TLR) IFNAR PD-1/PD-L1 ADC Payload	Inflammation/Immunology Cancer
TLR7 agonist 29 (Compound 1) is the agonist for *TLR7* with an EC₅₀ of 5.2 nM for human TLR7 (EC₅₀ for mouse TLR7 is 48.2 nM). TLR7 agonist 29 activates bone marrow-derived macrophages (BMDMs), stimulates myeloid cells in the tumor microenvironment, promotes the expression of PD-L1, CD86 and IFN-α. TLR7 agonist 29 can be used as payload for synthesis of ADC .

HY-153071

TLR7 agonist 6	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 6 (compound IIb-19) is an *TLR7* agonist with an EC₅₀ value of 1.0 nM .

HY-N16231

3A-MPLA ammonium	Toll-like Receptor (TLR)	Inflammation/Immunology
3A-MPLA ammonium, a monophosphoryl rri-acyl lipid A, is a TLR-4 agonist .

HY-150501

Diprovocim-X	Toll-like Receptor (TLR)	Inflammation/Immunology
Diprovocim-X (compound 35) is a potent *TLR1/TLR2* (toll-like receptor 1/2) agonist, with EC₅₀ values of 0.14 and 0.75 nM for hTLR1/TLR2 and mTLR1/TLR2, respectively. Diprovocim-X is a potent adjuvant in vivo in mice, and serves to stimulate the adaptive immune response .

HY-177648

Nelitolimod	Toll-like Receptor (TLR)	Cancer
Nelitolimod, a CpG oligonucleotide, is a TLR9 agonist.

HY-147236

TLR7/8 agonist 7	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7/8 agonist 7 (compound 10) is a **TLR7/8 agonist*. TLR7/8 agonist* 7 activates a variety of immune cells and it can be used to synthesize immune stimulating antibody conjugate (ISAC) molecules. TLR7/8 agonist 7 can be used for the research of immunity .

HY-141454

TLR8 agonist 2	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR8 agonist 2 is a potent and selective *TLR8* agonist with an EC₅₀ of 3 nM for human TLR8. TLR8 agonist 2 shows less active against human TLR7 (EC₅₀ of 33.33 μM) .

HY-163829

TLR2 agonist 1	Toll-like Receptor (TLR) NF-κB	Cancer
TLR2 agonist 1 (Compound R-7d) is an agonist for human toll-like receptor 2 (TLR 2) with an EC₅₀ of 116 pM. TLR2 agonist 1 enhances NF-κB promoter activation through TLR2/TLR1 heterodimers .

HY-179007

TLR7 agonist 31	Toll-like Receptor (TLR)	Cancer
TLR7 agonist 31 (Compound 116) is a *TLR7* agonist, with an EC₅₀ of 31 nM. TLR7 agonist 31 can be used in the research of cancer .

HY-145960A

*MC-Val-Cit-PAB-Amide-TLR7 agonist* 4 formic**	EGFR Toll-like Receptor (TLR)	Inflammation/Immunology
MC-Val-Cit-PAB-Amide-TLR7 agonist 4 formic (example 15) is a *HER2-TLR7* and *HER2-TLR8* immune agonist conjugate .

HY-177300

TLR7/8 agonist 13	Toll-like Receptor (TLR) HBV IFNAR Interleukin Related	Infection Inflammation/Immunology
TLR7/8 agonist 13 is an orally active dual agonist of *TLR7* (lowest effective concentrations (LEC) [hTLR7] = 1.6 μM) and *TLR8* (LEC [hTLR8] = 1.6 μM). TLR7/8 agonist 13 exhibits agonistic activity against human peripheral blood mononuclear cells (hPBMCs) (LEC [hPBMC] = 0.5 μM). TLR7/8 agonist 13 induces endogenous IFNα, activating myeloid dendritic cells and monocytes toward a TH1 phenotype in mice and cynomolgus monkeys. TLR7/8 agonist 13 reduces viral load and HBV surface antigen expression in a mouse model of chronic AAV-HBV infection. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, which may promote HBV antigen-specific CD8 T cell-mediated responses. TLR7/8 agonist 13 can be used to study hepatitis B virus .

HY-179275

TLR7 agonist 33	Toll-like Receptor (TLR)	Cancer
TLR7 agonist 33 (Compound 141) is a potent *TLR7* activator with an EC₅₀ of 1 nM. TLR7 agonist 33 can be used for cancer research .

Cat. No.	Product Name	Type

HY-13740G

Resiquimod R848; S28463	Fluorescent Dyes
Resiquimod (R848) (GMP) is Resiquimod (HY-13740) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist. Resiquimod (GMP) can induce human mMDSC to mature into inflammatory macrophages .

HY-107202GL

Polyinosinic-polycytidylic acid (GMP Like)

Poly(I:C) (GMP Like)

Fluorescent Dyes

Polyinosinic-polycytidylic acid (Poly(I:C)) (GMP Like) is the GMP Like class Polyinosinic-polycytidylic acid (HY-107202), and can be used as pharmaceutical excipients. Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis .

HY-P9994

Pertuzumab zuvotolimod

SBT6050

Fluorescent Dyes

Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .

HY-20457G

TL8-506	Fluorescent Dyes
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC₅₀ of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy .

HY-111582G

BBIQ (GMP)	Fluorescent Dyes
BBIQ (GMP) is BBIQ (HY-111582) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BBIQ is a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC₅₀ of  59.1 nM. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses .

Cat. No.	Product Name	Type

HY-W250113

Zymosan A 2 Publications Verification Zymosan A from Saccharomyces cerevisiae	Biochemical Assay Reagents
Zymosan A (Zymosan A from Saccharomyces cerevisiae) is a *TLR2* agonist, that targeting TLRs can prevent and suppress IR-induced intestinal injury. Zymosan A exhibits a significant radioprotective effect, and protects IR-induced intestinal injury in mice. Zymosan A promotes the regeneration of intestinal stem cells (ISCs), after IR injury .

HY-13740G

Resiquimod R848; S28463	Biochemical Assay Reagents
Resiquimod (R848) (GMP) is Resiquimod (HY-13740) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist. Resiquimod (GMP) can induce human mMDSC to mature into inflammatory macrophages .

HY-W782032

3D-Monophosphoryl Lipid A-5 3D-MPLA-5	Biochemical Assay Reagents
3D-Monophosphoryl Lipid A-5 (3D-MPLA-5) is a TLR agonist that serves as a vaccine adjuvant and enhances the immunogenicity of vaccines .

HY-NP134

Flagellin from S. typhimurium

Biochemical Assay Reagents

Flagellin from S. typhimurium is a potent TLR5 agonist. Flagellin from S. typhimurium activates immune cells and inhibits the activity of melanoma cells. Flagellin from S. typhimurium activates the NF-κB pathway dependent on the TLR5/MyD88/TRAF6 signaling axis in cells. Flagellin from S. typhimurium induces a proinflammatory response in the primary chicken hepatocyte-nonparenchymal cell co-culture system by promoting IL-8 production, inhibiting IL-10 production, and increasing the IFN-γ/IL-10 ratio. Flagellin from S. typhimurium can be used for research on melanoma and inflammatory diseases .

HY-107202GL

Polyinosinic-polycytidylic acid (GMP Like)

Poly(I:C) (GMP Like)

Biochemical Assay Reagents

HY-159671

3D-Monophosphoryl Lipid (14) 3D-MPL (14)	Biochemical Assay Reagents
3D-Monophosphoryl Lipid (14) (3D-Monophosphoryl Lipid (14)) is a *TLR4* agonist that can be used as a vaccine adjuvant to enhance the immunogenicity of vaccines .

HY-20457G

TL8-506	Biochemical Assay Reagents
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC₅₀ of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy .

HY-159672

3D-Monophosphoryl Lipid (12,16) 3D-MPL (12,16)	Biochemical Assay Reagents
3D-Monophosphoryl Lipid (12,16) (3D-MPL (12,16)) is a *TLR4* agonist that can be used as a vaccine adjuvant to enhance the immunogenicity of vaccines .

HY-111582G

BBIQ (GMP)	Biochemical Assay Reagents
BBIQ (GMP) is BBIQ (HY-111582) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BBIQ is a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC₅₀ of  59.1 nM. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses .

Cat. No.	Product Name	Target	Research Area

HY-P1180A

Pam3CSK4 TFA Maximum Cited Publications 19 Publications Verification Pam3Cys-Ser-(Lys)4 TFA	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
Pam3CSK4 TFA is a toll-like receptor 1/2 (TLR1/2) agonist with an EC₅₀ of 0.47 ng/mL for human TLR1/2 .

HY-P1439

RS 09 15+ Cited Publications	Toll-like Receptor (TLR) NF-κB	Inflammation/Immunology
RS 09 is an LPS (HY-D1056) peptide mimic and *TLR4* agonist. RS 09 can bind to *TLR-4* and activate NF-κB. RS 09 can function as an adjuvant in vivo, enhancing the antigen-specific immune response .

HY-P2036A

FSL-1 TFA 4 Publications Verification	Toll-like Receptor (TLR) MMP HSV Antibiotic	Infection
FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection . FSL-1 TFA induces MMP-9 production through *TLR2* and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells .

HY-P2036

FSL-1 4 Publications Verification	Toll-like Receptor (TLR) Antibiotic	Infection
FSL-1, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection .

HY-P1180

Pam3CSK4 Pam3Cys-Ser-(Lys)4	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
Pam3CSK4 is a toll-like receptor 1/2 (TLR1/2) agonist with an EC₅₀ of 0.47 ng/mL for human TLR1/2 .

HY-P1181A

Pam2CSK4 TFA 1 Publications Verification	Toll-like Receptor (TLR) NO Synthase IKK Akt PKC NF-κB p38 MAPK Interleukin Related	Cardiovascular Disease Infection Inflammation/Immunology Cancer
Pam2CSK4 TFA is a *TLR2* agonist. Pam2CSK4 TFA induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 TFA activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. *TLR2* activation triggered by Pam2CSK4 TFA expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 TFA acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 TFA can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis .

HY-P1181

Pam2CSK4	Toll-like Receptor (TLR) NO Synthase IKK Akt PKC NF-κB p38 MAPK Interleukin Related	Cardiovascular Disease Infection Inflammation/Immunology Cancer
Pam2CSK4 is a *TLR2* agonist. Pam2CSK4 induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. *TLR2* activation triggered by Pam2CSK4 expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis .

HY-P1439A

RS 09 TFA 15+ Cited Publications	Toll-like Receptor (TLR) NF-κB	Inflammation/Immunology
RS 09 TFA is an LPS (HY-D1056) peptide mimic and *TLR4* agonist. RS 09 TFA can bind to *TLR-4* and activate NF-κB. RS 09 TFA can function as an adjuvant in vivo, enhancing the antigen-specific immune response .

HY-P10586A

Macrophage-activating lipopeptide 2 TFA MALP-2 TFA	Toll-like Receptor (TLR) NO Synthase	Cardiovascular Disease Metabolic Disease
Macrophage-activating lipopeptide 2 TFA is an agonist of Toll like receptors *TLR-2/TLR-6. Macrophage-activating lipopeptide-2 enhances endothelial nitric oxide synthase (eNOS*) phosphorylation and endothelial cell release of NO, thereby improving vasodilation. Macrophage-activating lipopeptide-2 enhances endothelial adhesion of white blood cells and improve perfusion recovery and collateral growth in the hind limbs of hypercholesterolemic Apoe deficient mice undergoing experimental femoral artery ligation (FAL) .

HY-P1405

Pam3CSK4-Biotin Pam3Cys-Ser-(Lys)4-Biotin	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
Pam3CSK4-Biotin is biotinylated Pam3CSK4. Pam3CSK4-Biotin is a Toll-like receptor 1/2 (TLR1/2) agonist .

HY-P10586

Macrophage-activating lipopeptide 2 MALP-2	Toll-like Receptor (TLR) NO Synthase	Cardiovascular Disease
Macrophage-activating lipopeptide 2 (MALP-2) is an agonist of Toll like receptors *TLR-2/TLR-6. Macrophage-activating lipopeptide-2 can enhance endothelial nitric oxide synthase (eNOS*) phosphorylation and endothelial cell release of NO, thereby improving vasodilation. Macrophage-activating lipopeptide-2 can enhance endothelial adhesion of white blood cells and improve perfusion recovery and collateral growth in the hind limbs of hypercholesterolemic Apoe deficient mice undergoing experimental femoral artery ligation (FAL) .

HY-P1405A

Pam3CSK4-Biotin TFA Pam3Cys-Ser-(Lys)4-Biotin TFA	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
Pam3CSK4-Biotin (Pam3Cys-Ser-(Lys)4-Biotin) TFA is biotinylated Pam3CSK4. Pam3CSK4-Biotin TFA is a Toll-like receptor 1/2 (TLR1/2) agonist .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9994

Pertuzumab zuvotolimod SBT6050	Antibody-Drug Conjugates (ADCs) EGFR Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a *TLR8* agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .

HY-P990239

Anti-Human/Mouse GRP78 Antibody (N88)	HSP Akt Interleukin Related	Inflammation/Immunology Cancer
Anti-Human/Mouse GRP78 Antibody (N88) is an anti-human/mouse GRP78 IgG1 monoclonal antibody. Anti-Human/Mouse GRP78 Antibody (N88) can activate the Akt signaling pathway. Anti-Human/Mouse GRP78 Antibody (N88) can inhibit the expression of inflammatory factors and plasminogen activator inhibitors induced by TLR agonists. Anti-Human/Mouse GRP78 Antibody (N88) can be used for research on inflammation conditions. Anti-Human/Mouse GRP78 Antibody (N88) can be used for immunoprecipitation .

HY-P992458

SBT8230	Toll-like Receptor (TLR) HBV	Infection
SBT8230 is an ASGR1-targeted *TLR8* agonist and an ASGR1-TLR8 immune TAC conjugate. SBT8230 achieves liver enrichment via conjugation with an anti-ASGR1 antibody, activates myeloid cells and induces anti-HBV immune responses. SBT8230 is applicable to research on chronic hepatitis B infection. The corresponding isotype control is: Human lgG1 kappa,lsotype Control (HY-P99001) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0217

Benzoylaconine 1 Publications Verification Benzoylaconitine; Isaconitine; Pikraconitin	Alkaloids Classification of Application Fields Other Alkaloids Ranunculaceae Other Diseases Aconitum carmichaeli Debx. Plants Disease Research Fields Source Classification	Angiotensin-converting Enzyme (ACE) Reactive Oxygen Species (ROS) Toll-like Receptor (TLR) NF-κB COX NO Synthase p38 MAPK P-glycoprotein
Benzoylaconine (Benzoylaconitine) is an orally active monoester alkaloid found in the traditional Chinese medicine Aconitum carmichaelii. Benzoylaconine is an ACE2 agonist (EC₅₀: 1.5 μM) with antihypertensive and anti-heart failure effects. Benzoylaconine inhibits TLR-induced MAPK and NF-κB pathways to exert anti-inflammatory effects. Benzoylaconine upregulates the protein levels of P-gp, MRP2, and has anti-tumor effects .

HY-N1990

Gypenoside XLIX 2 Publications Verification	Cardiovascular Disease Triterpenes Structural Classification Classification of Application Fields Terpenoids Cucurbitaceae Plants Gynostemma pentaphyllum (Thunb.) Makino Disease Research Fields Source Classification	PPAR Sirtuin Keap1-Nrf2 Toll-like Receptor (TLR) NF-κB Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) Apoptosis Pyroptosis Autophagy
Gypenoside XLIX is a multifunctional bioactive compound that can be isolated from Gynostemma pentaphyllum, with a K_a value of 1.58 μM for its binding to SIRT1. Gypenoside XLIX acts as a PPAR-α agonist. It inhibits the activation of *TLR4*-mediated NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with sepsis-induced liver disease. Gypenoside XLIX targets SIRT1 to block YAP-NLRP3 activation and improve sepsis-induced cardiomyopathy. Gypenoside XLIX inhibits apoptosis (Apoptosis), pyroptosis (Pyroptosis), autophagy (Autophagy), lipid peroxidation, pro-inflammatory cytokines and anti-inflammatory cytokines. Gypenoside XLIX alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, and mitigates sepsis-associated encephalopathy by targeting PPAR-α. Gypenoside XLIX prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation. Gypenoside XLIX inhibits the expression and activity of vascular cell adhesion molecule-1 in cytokine-induced human endothelial cells. Gypenoside XLIX is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis and chronic inflammation .

HY-113093

Ethyl glucuronide	Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Saccharides Source Classification	Endogenous Metabolite Toll-like Receptor (TLR)
Ethyl glucuronide is an endogenous metabolite. Ethyl glucuronide is the metabolite of ethanol. Ethyl glucuronide is a biomarker for ethanol exposure that accumulates in hair and reflects the alcohol intake over a time period. Ethyl glucuronide is the agonist for *TLR4* .

HY-N2110

Phellopterin	Structural Classification Classification of Application Fields Coumarins Phenylpropanoids Umbelliferae Helogyne apaloidea Nutt. Plants Inflammation/Immunology Disease Research Fields Source Classification	Akt Sirtuin Integrin STAT PI3K Apoptosis ERK PPAR PKC Toll-like Receptor (TLR) HIV
Phellopterin, an orally active furocoumarin with multiple biological activities. Phellopterin is a partial agonist of the central benzodiazepine receptors. Phellopterin exerts anti-inflammatory effects by upregulating SIRT1, downregulating ICAM-1 (reducing chronic inflammation, aiding diabetic ulcer healing), inhibiting STAT3 phosphorylation (easing atopic dermatitis inflammation), regulating Akt/PKC pathways (lowering TNF-α-induced VCAM-1 to block monocyte adhesion), and inhibiting *TLR4/NF-κB* pathway and macrophage M2 polarization (alleviating colitis-related cancers). Phellopterin suppresses ovarian cancer progression via inhibiting the PU.1/CLEC5A/PI3K-AKT loop (inducing cell cycle arrest, apoptosis, DNA damage). Phellopterin alleviates murine diabetes by promoting adipocyte differentiation and increasing PPARγ. Phellopterin also has anti-HSV-1 activity. Phellopterin can be used for studying anti-inflammation, anti-cancer (e.g., ovarian cancer, colitis cancer), blood glucose lowering, anti-diabetes, and anti-virus .

HY-N16021

4A-MPLA ammonium	Structural Classification Lipid	Toll-like Receptor (TLR) Cdc42-binding kinase Galectin
4A-MPLA ammonium is an orally active *TLR4* agonist. 4A-MPLA ammonium induces TLR4 endocytosis dependent on Cdc42 and galectin-3, triggering TRIF-mediated signaling and sustained IFN-β production. 4A-MPLA ammonium promotes lipid droplet formation, upregulates interferon-stimulated genes and type I IFN signaling genes, downregulates lysosome/phagosome function genes, and modulates tolerogenic dendritic cell function. 4A-MPLA ammonium can be used for the research of colitis .

HY-N16231

3A-MPLA ammonium	Lipid	Toll-like Receptor (TLR)
3A-MPLA ammonium, a monophosphoryl rri-acyl lipid A, is a TLR-4 agonist .

HY-N2110R

Phellopterin (Standard)	Structural Classification Coumarins Phenylpropanoids Umbelliferae Helogyne apaloidea Nutt. Plants Source Classification	Reference Standards Akt Sirtuin Integrin STAT PI3K Apoptosis ERK PPAR PKC Toll-like Receptor (TLR) HIV
Phellopterin (Standard) is the analytical standard of Phellopterin. Phellopterin, an orally active furocoumarin with multiple biological activities. Phellopterin is a partial agonist of the central benzodiazepine receptors. Phellopterin exerts anti-inflammatory effects by upregulating SIRT1, downregulating ICAM-1 (reducing chronic inflammation, aiding diabetic ulcer healing), inhibiting STAT3 phosphorylation (easing atopic dermatitis inflammation), regulating Akt/PKC pathways (lowering TNF-α-induced VCAM-1 to block monocyte adhesion), and inhibiting *TLR4/NF-κB* pathway and macrophage M2 polarization (alleviating colitis-related cancers). Phellopterin suppresses ovarian cancer progression via inhibiting the PU.1/CLEC5A/PI3K-AKT loop (inducing cell cycle arrest, apoptosis, DNA damage). Phellopterin alleviates murine diabetes by promoting adipocyte differentiation and increasing PPARγ. Phellopterin also has anti-HSV-1 activity. Phellopterin can be used for studying anti-inflammation, anti-cancer (e.g., ovarian cancer, colitis cancer), blood glucose lowering, anti-diabetes, and anti-virus.

HY-N16013

FP-18 disodium	Lipid	Toll-like Receptor (TLR)
FP-18 disodium, a *TLR-4* agonist, is a vaccine adjuvant.

HY-N16020

α-Glucosyl FP20 sodium	Lipid	Toll-like Receptor (TLR)
α-Glucosyl FP20 sodium, a *TLR-4* agonist, is a vaccine adjuvant.

HY-N16009

α-Rhamnosyl FP20 sodium	Lipid	Toll-like Receptor (TLR)
α-Rhamnosyl FP20 sodium, a *TLR-4* agonist, is a vaccine adjuvant.

HY-N16024

FP-20 sodium	Lipid	Toll-like Receptor (TLR)
FP-20 sodium, a selective *TLR4* agonist, is a vaccine adjuvant. FP-20 sodium induces MAPK- and NLRP3-dependent inflammasome activation. FP20 shows no toxicity in mouse vaccination experiments with OVA antigen and induces IgG production .

HY-N15893

α-Galactosyl FP20 sodium	Lipid	Toll-like Receptor (TLR)
α-Galactosyl FP20 sodium, a *TLR-4* agonist, is a vaccine adjuvant.

Cat. No.	Product Name	Chemical Structure

HY-113093S

Ethyl glucuronide-d5
Ethyl glucuronide-d₅ is the deuterium labeled Ethyl glucuronide (HY-113093) . Ethyl glucuronide is an endogenous metabolite. Ethyl glucuronide is the metabolite of ethanol. Ethyl glucuronide is a biomarker for ethanol exposure that accumulates in hair and reflects the alcohol intake over a time period. Ethyl glucuronide is the agonist for *TLR4* .

HY-13740S

Resiquimod-d5 1 Publications Verification
Resiquimod-d₅ is deuterium labeled Resiquimod. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α .

HY-B0180S1

Imiquimod-d9
Imiquimod-d₉ is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .

HY-B0180S

Imiquimod-d6
Imiquimod-d₆ is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .

HY-B0180S2

Imiquimod-d7
Imiquimod-d₇ (R 837-d₇) is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .

Cat. No.	Product Name		Classification

HY-159102

PVP-037.2		Azide
PVP-037.2 is a *TLR7/8* agonist. PVP-037.2 can serve as an adjuvant to enhance vaccine-induced T_H1 type immune responses, increasing the production of antigen-specific antibodies IgG1 and IgG2c .

HY-159100

PVP-037		Azide
PVP-037 is a potent *TLR7* and *TLR8* agonist adjuvant. PVP-037 shows broad innate immune activation and enhances vaccine immune responses .

HY-154361

TLR7 agonist 13		Alkynes
TLR7 agonist 13 is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7) . TLR7 agonist 13 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name		Classification

HY-146245

ODN 1826 Maximum Cited Publications 10 Publications Verification CpG 1826		CpG ODNs
ODN 1826 is a class B CpG ODN (oligodeoxynucleotide) and *TLR9* agonist. ODN 1826 induces NO and iNOS production and enhances Apoptosis. ODN 1826 enhances immune surveillance. ODN 1826 increases aortic atherosclerotic plaque size. ODN 1826 has antitumor activity against lung cancer, glioma and melanoma .

HY-146244

Agatolimod 1 Publications Verification ODN 2006; PF-3512676; CpG 7909; ODN 7909		CpG ODNs
Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a *TLR9* agonist and immunomodulator with an EC₅₀ of 180 nM against human *TLR9. Agatolimod activates and upregulates the expression of both TLR9* and *TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19*, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis .

HY-150724

ODN 1018 2 Publications Verification 1018 ISS		CpG ODNs
ODN 1018 (1018 ISS) is a *TLR9* agonist and immune modulator. ODN 1018 exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 triggers sustained suppression of allergic airway inflammation. ODN 1018 can be used for the research of allergic asthma and systemic lupus erythematosus .

HY-150218

Agatolimod sodium 1 Publications Verification ODN 2006 sodium; ODN 7909 sodium; PF-3512676 sodium; CpG 7909 sodium		CpG ODNs
Agatolimod sodium (ODN 2006) is a class B CpG ODN and is a *TLR9* agonist. Agatolimod sodium can be used as vaccine adjuvant. Agatolimod sodium can be used for the research of cancer. Sequence: 5’-TCGTCGTTTTGTCGTTTTGTCGTT-3’ .

HY-150743

ODN 2395		CpG ODNs
ODN 2395 is a C class oligodeoxynucleotide and can be used as vaccine adjuvant. ODN 2395 is also a *TLR9* agonist. ODN 2395 can be used in the research of immunological vaccines. Sequence: 5'-tcgtcgttttcggcgc:gcgccg-3' (Note: The bases are phosphorothioate; ODN 2395 contains the partial palindromic sequence cggcgc:gcgccg) .

HY-146245C

ODN 1826 sodium Maximum Cited Publications 10 Publications Verification CpG 1826 sodium		CpG ODNs
ODN 1826 sodium is a class B CpG ODN (oligodeoxynucleotide) and *TLR9* agonist. ODN 1826 sodium induces NO and iNOS production and enhances Apoptosis. ODN 1826 sodium enhances immune surveillance. ODN 1826 sodium increases aortic atherosclerotic plaque size. ODN 1826 sodium has antitumor activity against lung cancer, glioma and melanoma .

HY-150741

ODN 2216 1 Publications Verification		CpG ODNs
ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a *TLR9* agonist. ODN 2216 interacts with *TLR9* in the lysosomes of CD4 ⁺ T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 ⁺ T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 ⁺ T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .

HY-150750

ODN M362		CpG ODNs
ODN M362, a class C oligodeoxynucleotide, is a *TLR-9* agonist and can be used as a vaccine adjuvant. ODN M362 induces cancer cell apoptosis .

HY-150724C

ODN 1018 sodium 2 Publications Verification 1018 ISS sodium		CpG ODNs
ODN 1018 (1018 ISS) sodium is a *TLR9* agonist and immune modulator. ODN 1018 sodium exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 sodium triggers sustained suppression of allergic airway inflammation. ODN 1018 sodium can be used for the research of allergic asthma and systemic lupus erythematosus .

HY-150741C

ODN 2216 sodium 1 Publications Verification		CpG ODNs
ODN 2216 sodium is a type A CpG oligodeoxynucleotide vaccine adjuvant and a *TLR9* agonist. ODN 2216 sodium interacts with *TLR9* in the lysosomes of CD4 ⁺ T cells and activates feedback-dependent signaling pathways. ODN 2216 sodium induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 sodium not only induces the differentiation of CD4 ⁺ T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 ⁺ T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 sodium is widely used in studies related to breast cancer and systemic lupus erythematosus .

HY-150217

CpG ODN 10101 2 Publications Verification ODN 10101		CpG ODNs
CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .

HY-111582

BBIQ		Adjuvant
BBIQ is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC₅₀ of 59.1 nM for human TLR7. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses .

HY-150726

ODN 1668 1 Publications Verification		CpG ODNs
ODN 1668, a class B CpG ODN (oligodeoxynucleotide), is a *TLR-9* agonist. ODN 1668 has strong immune regulatory properties, can enhance the level of antibody IgG2 subtype, promote the immune response of T cells and B cells, and can be used in the study of vaccine adjuvants. In addition, CpG ODN 1668 induces an antimicrobial immune response via a CaTLR9 dependent pathway in groupers. Sequence: 5'-tccatgacgttcctgatgct-3’ .

HY-150726C

ODN 1668 sodium 1 Publications Verification		CpG ODNs
ODN 1668 sodium, a class B CpG ODN (oligodeoxynucleotide), is a *TLR-9* agonist. ODN 1668 sodium has strong immune regulatory properties, can enhance the level of antibody IgG2 subtype, promote the immune response of T cells and B cells, and can be used in the study of vaccine adjuvants. In addition, CpG ODN 1668 sodium induces an antimicrobial immune response via a CaTLR9 dependent pathway in groupers. Sequence: 5'-tccatgacgttcctgatgct-3’ .

HY-150750A

ODN M362 sodium		CpG ODNs
ODN M362 sodium is a *TLR9* agonist that acts as a vaccine adjuvant. ODN M362 sodium activates mouse splenocytes, induces apoptosis in human hepatocellular carcinoma cells, upregulates proinflammatory cytokines in human hepatocellular carcinoma cells, and inhibits the proliferation of human hepatocellular carcinoma cells. ODN M362 sodium upregulates the expression of *TLR9/TLR6*, activates downstream signaling pathways via IRAK4 and IRF7, and strongly amplifies antigen-specific cellular immune responses to participate in innate immune activation. ODN M362 sodium can be used in research related to hepatocellular carcinoma and breast cancer .

HY-N15936

a15:0-i15:0 PE		Phospholipids
a15:0-i15:0 PE is a diacyl phosphatidylethanolamine with two branched chains. a15:0-i15:0 PE is a non-canonical *TLR2-TLR1* heterodimer agonist and has immunogenic activity. a15:0-i15:0 PE activates T cells and DC signaling and shows anti-inflammatory activity. a15:0-i15:0 PE induces TNFα and IL-6 production. a15:0-i15:0 PE is a the major component (approximately 50%) of A. muciniphila’s lipid membrane .

HY-150217A

CpG ODN 10101 sodium 2 Publications Verification ODN 10101 sodium		CpG ODNs
CpG ODN 10101 sodium, a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist. CpG ODN 10101 sodium is a potent inducer of cytokine/chemokine expression ex vivo when used in combination with HH2(VQLRIRVAVIRA-NH2). CpG ODN 10101 sodium induces IFN- secretion from dendritic cells (DCs) and stimulates B-cells.CpG ODN 10101 sodium has antiviral and immunomodulatory properties that can influence chronic infection with HCV .

HY-150748A

ODN D-SL01 sodium		CpG ODNs
ODN D-SL01 sodium, a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. ODN D-SL01 sodium has strong immunostimulatory activity in a variety of vertebrate species and has anticancer activity. ODN D-SL01 sequence: 5'- T-C-G-C-G-A-C-G-T-T-C-G-C-C-C-G-A-C-G-T-T-C-G-G-T-A-3' .

HY-150724B

FITC-labeled ODN 1018 sodium		CpG ODNs
FITC-labeled ODN 1018 (sodium),an oligodeoxynucleotide, is a *TLR-9* agonist. FITC-labeled ODN 1018 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-150743A

Biotin-labeled ODN 2395 sodium		CpG ODNs
Biotin-labeled ODN 2395 (sodium), a C class oligodeoxynucleotide, is a *TLR9* agonist. Biotin-labeled ODN 2395 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-148511A

Vidutolimod sodium CMP-001 sodium		CpG ODNs
Vidutolimod sodium is a CpG-A oligodeoxynucleotide. Vidutolimod sodium is a Toll-like receptor 9 (TLR9) agonist, which activates plasmacytoid dendritic cells (pDCs) and triggers interferon alpha (IFNα) release, leading to a cascade of anti-tumor immune effects.

HY-146245F

FAM-labeled ODN 1826 sodium 1 Publications Verification		CpG ODNs
FAM-labeled ODN 1826 sodium, a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. FAM-labeled ODN 1826 sodium can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy or flow cytometry.

HY-146245A

Biotin-labeled ODN 1826 sodium		CpG ODNs
Biotin-labeled ODN 1826 (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. Biotin-labeled ODN 1826 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-150743C

ODN 2395 sodium		CpG ODNs
ODN 2395 sodium is a C class oligodeoxynucleotide and can be used as vaccine adjuvant. ODN 2395 sodium is also a *TLR9* agonist. ODN 2395 sodium can be used in the research of immunological vaccines. Sequence: 5'-tcgtcgttttcggcgc:gcgccg-3' .

HY-150743B

FITC-labeled ODN 2395 sodium		CpG ODNs
FITC-labeled ODN 2395 (sodium), a C class oligodeoxynucleotide, is a *TLR9* agonist. FITC-labeled ODN 2395 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-150742A

ODN 2336 sodium		CpG ODNs
ODN 2336 sodium is a A-Class CpG ODN (oligodeoxynucleotides), is a potent *TLR9* agonist. ODN 2336 sodium induces the production of IFN-α. ODN 2336 sodium up-regulates the expression of IP-10 mRNA and IL-18 mRNA. ODN 2336 sodium can be used as adjuvant of vaccines .

HY-150212

Tilsotolimod IMO-2125		Antisense Oligonucleotides
Tilsotolimod (IMO-2125) is a *TLR9* agonist. Tilsotolimod activates the *TLR9* signaling pathway, triggers downstream pro-inflammatory and immunostimulatory pathways, enhances the uptake and killing of cancer cells, and induces adaptive immune responses. Tilsotolimod is applicable to research related to melanoma and colorectal cancer .

HY-150212A

Tilsotolimod sodium IMO-2125 sodium		Antisense Oligonucleotides
Tilsotolimod (IMO-2125) sodium is a *TLR9* agonist. Tilsotolimod sodium activates the *TLR9* signaling pathway, triggers downstream pro-inflammatory and immunostimulatory pathways, enhances the uptake and killing of cancer cells, and induces adaptive immune responses. Tilsotolimod sodium is applicable to research related to melanoma and colorectal cancer .

HY-146244A

Biotin-labeled agatolimod sodium		CpG ODNs
Biotin-labeled agatolimod (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. Biotin-labeled agatolimod (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-150741B

FITC-labeled ODN 2216 sodium		CpG ODNs
FITC-labeled ODN 2216 (sodium) is a human-specific *TLR9* (toll-like receptor 9) ligand or agonist. FITC-labeled ODN 2216 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-177058

DSP30		CpG ODNs
DSP30 is a phosphorothioate cpG-oligodeoxynucleotide and a *TLR9* agonist. DSP30 can activate immune system cells, including B cells and dendritic cells, by inducing proliferation and cytokine production.DSP30 can enhance the immunosuppressive function of bone marrow-multipotent mesenchymal stromal cells (BM-MSC). DSP30 combined with interleukin 2 (IL2) is an effective mitotic stimulant in B-cell disorders. DSP30 can be used for the genetic characteristic research and analysis of chronic lymphocytic leukemia (CLL) .

HY-177648

Nelitolimod		CpG ODNs
Nelitolimod, a CpG oligonucleotide, is a TLR9 agonist.

HY-150219

ODN M326 CpG-ODN M326		CpG ODNs
ODN M326 (CpG-ODN M326) is a potent *TLR9* agonist. ODN M326 induces the production of TNF. ODN M326 can be used as a vaccine adjuvant .

HY-150741A

Biotin-labeled ODN 2216 sodium		CpG ODNs
Biotin-labeled ODN 2216 (sodium) is a human-specific *TLR9* (toll-like receptor 9) ligand or agonist. Biotin-labeled ODN 2216 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-150742

ODN 2336		CpG ODNs
ODN 2336 is a A-Class CpG ODN (oligodeoxynucleotides), is a potent *TLR9* agonist. ODN 2336 induces the production of IFN-α. ODN 2336 up-regulates the expression of IP-10 mRNA and IL-18 mRNA. ODN 2336 can be used as adjuvant of vaccines .

HY-177648A

Nelitolimod sodium		CpG ODNs
Nelitolimod sodium, a CpG oligonucleotide, is a TLR9 agonist.

HY-160040

Cobitolimod		Antisense Oligonucleotides
Cobitolimod is a DNA oligonucleotide agonist of *TLR-9* with anti-inflammatory activity. Cobitolimod suppresses Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway .

HY-150748

ODN D-SL01		CpG ODNs
ODN D-SL01, a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. ODN D-SL01 has strong immunostimulatory activity in a variety of vertebrate species and has anticancer activity. ODN D-SL01 sequence: 5'- T-C-G-C-G-A-C-G-T-T-C-G-C-C-C-G-A-C-G-T-T-C-G-G-T-A-3' .

HY-150724A

Biotin-labeled ODN 1018 sodium		CpG ODNs
Biotin-labeled ODN 1018 (sodium), an oligodeoxynucleotide, is a *TLR-9* agonist. Biotin-labeled ODN 1018 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-177635

GNKG168		Antisense Oligonucleotides
GNKG168 is a synthetic, 21-mer, unmethylated CpG oligodeoxynucleotide. It acts as a TLR9 agonist with immunostimulatory activity.

HY-177635A

GNKG168 sodium		Antisense Oligonucleotides
GNKG168 sodium is a synthetic, 21-mer, unmethylated CpG oligodeoxynucleotide. It acts as a TLR9 agonist with immunostimulatory activity.

HY-160040A

Cobitolimod sodium		Antisense Oligonucleotides
Cobitolimod sodium is a DNA oligonucleotide agonist of *TLR-9* with anti-inflammatory activity. Cobitolimod sodium inhibits Th17 cells and induces anti-inflammatory FoxP3 and IL-10 expression, inhibiting the IL-17 signaling pathway .

HY-177642

Litenimod Li28		CpG ODNs
Litenimod is potent type B agonist of toll Like receptor 9 (TLR9), triggering both innate and adaptive immune response.

HY-177642A

Litenimod sodium Li28 sodium sodium		CpG ODNs
Litenimod sodium is potent type B agonist of toll Like receptor 9 (TLR9), triggering both innate and adaptive immune response.

HY-150219A

ODN M326 sodium CpG-ODN M326 sodium		CpG ODNs
ODN M326 (CpG-ODN M326) sodium is a potent *TLR9* agonist. ODN M326 sodium induces TNF production and serves as a vaccine adjuvant .

HY-150726A

Biotin-labeled ODN 1668 sodium		CpG ODNs
Biotin-labeled ODN 1668 (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. Biotin-labeled ODN 1668 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-146244B

FITC-labeled agatolimod sodium		CpG ODNs
FITC-labeled agatolimod (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. FITC-labeled agatolimod (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-146245B

FITC-labeled ODN 1826 sodium		CpG ODNs
FITC-labeled ODN 1826 (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. FITC-labeled ODN 1826 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-150726B

FITC-labeled ODN 1668 sodium		CpG ODNs
FITC-labeled ODN 1668 (sodium), a class B CpG ODN (oligodeoxynucleotide), is a *TLR9* agonist. FITC-labeled ODN 1668 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-159753

HS105		Adjuvant
HS105 is a vaccine adjuvant and a key component in vaccines. Adjuvants can be divided into immunostimulants and delivery systems. Adjuvants can not only enhance the intensity and durability of immune responses, but also affect the type of immune responses. On the one hand, immunostimulants promote the production of antigen signals and co-stimulatory signals by targeting Toll-like receptors (TLRs) and other pattern recognition receptors (PRRs), leading to the maturation and activation of antigen presenting cells (APCs), thereby enhancing adaptive immune responses; on the other hand, delivery systems are carrier materials that promote antigen delivery by prolonging the bioavailability of loaded antigens and targeting antigens to lymph nodes or APCs. Several common adjuvants include: saponins, TLRs agonists, polysaccharides, nanoparticles, cytokines, and mucosal adjuvants .

Targets Recommended: Toll-like Receptor (TLR)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13740G

Resiquimod R848; S28463	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
Resiquimod (R848) (GMP) is Resiquimod (HY-13740) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist. Resiquimod (GMP) can induce human mMDSC to mature into inflammatory macrophages .

HY-20457G

TL8-506	Toll-like Receptor (TLR) Bacterial Interleukin Related	Inflammation/Immunology Cancer
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC₅₀ of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy .

HY-107202GL

Polyinosinic-polycytidylic acid (GMP Like) Poly(I:C) (GMP Like)	Toll-like Receptor (TLR) PKD HSP Bcl-2 Family Interleukin Related Apoptosis	Infection Inflammation/Immunology Cancer
Polyinosinic-polycytidylic acid (Poly(I:C)) (GMP Like) is the GMP Like class Polyinosinic-polycytidylic acid (HY-107202), and can be used as pharmaceutical excipients. Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

TLR agonists

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Natural
Products